|FOR IMMEDIATE RELEASE
Monday, September 29, 1997
First Grants For Innovative AIDS Vaccine Research
- Identify sites and mechanisms of viral and immune cell interactions
once the virus has attached to a cell.
- Develop novel approaches to analyzing the structure of HIV. New
knowledge of the biophysical characteristics of HIV's structure can
bring to light additional sites for attacking it.
- Improve the immune-stimulating ability of HIV proteins.
- Study the impact of newly described or less studied cell types of the
immune response to HIV. These studies may provide information on
how to improve existing vaccine candidates or additional therapeutic
- Explore the potential of new genetically engineered animal models.
- Study the mechanisms of action that may clarify the roles of HIV as
it interacts with immune cell receptors during infection. Such studies
may show researchers more opportunities to intervene in the infection
and disease processes.
- Develop new vaccine formulations to improve ways in which the
vaccine material is presented to the immune system. HIV is a quickly
mutating virus. The chances for a vaccine interfering with the virus'
progress are improved when scientists can identify better ways of
alerting the immune system to potential danger.
- Develop new vectors and improve existing ones. Vectors, or
carriers of vaccine materials and immune system stimulators, can
greatly enhance a vaccine's effectiveness.
The grantees are:
- Christopher C. Broder, Ph.D., Henry M. Jackson Foundation for the
Advancement of Military Medicine, Rockville, Md.
- John D. Clements, Ph.D., Tulane University, New Orleans, La.
- David M. Hone, Ph.D., Maryland Biotechnology Institute, Baltimore
- Steven A. Johnston, Ph.D., University of Texas Southwest Medical
- Gunter Kraus, Ph.D., University of Miami, Fla.
- Paul A. Luciw, Ph.D., University of California, Davis
- Roland M. Tisch, Ph.D., University of North Carolina, Chapel Hill
- Michael S. Marks, Ph.D., University of Pennsylvania, Philadelphia
- Harris Goldstein, M.D., Yeshiva University, New York City
- Anthony Devico, Ph.D., Maryland Biotechnology Institute, Baltimore
- Xiao-Fang Yu, M.D., D.Sc., Johns Hopkins University, Baltimore,
- Richard A. Koup, M.D., University of Texas Southwest Medical
- Peter M. Palese, Ph.D., Mount Sinai School of Medicine of the City
University of New York
- Paul V. Lehmann, M.D., Ph.D., Case Western Reserve University,
- David I. Watkins, Ph.D., University of Wisconsin, Madison
- Ruth E. Berggren, M.D., University of Colorado Health Sciences
- Boro Dropulic, B.Sc., Ph.D., Johns Hopkins University, Baltimore,
- Ronald I. Swanstrom, Ph.D., University of North Carolina, Chapel
- Mary K. Estes, Ph.D., Baylor College of Medicine, Houston, Texas
- Don C. Wiley, Ph.D., Children's Hospital, Boston, Mass.
- Paul W. Parren, Ph.D., Scripps Research Institute, San Diego, Calif.
- Mark A. Goldsmith, M.D., Ph.D., J. David Gladstone Institutes, San
- Kyung-Dall Lee, Ph.D., University of Michigan, Ann Arbor
- George J. Cianciolo, Ph.D., Duke University, Durham, N.C.
- Nancy L. Haigwood, Ph.D., Seattle Biomedical Research Institute,
- Linqi Zhang, Ph.D., Aaron Diamond AIDS Research Center, New
- Leonidas Stamatatos, Ph.D., Aaron Diamond AIDS Research Center,
New York City
- Robert J. Collier, Ph.D., Harvard University, Cambridge, Mass.
- William C. Olson, Ph.D., Progenics Pharmaceuticals, Inc.,
- Nicholas Carbonetti, Ph.D., University of Maryland, Baltimore
- Raymond J. Langley, Ph.D., Virion Systems, Inc., Rockville, Md.
- Richard C. Duke, M.Sc., Ph.D., University of Colorado Health
Sciences Center, Denver
- William C. Cheevers, Ph.D., Washington State University, Pullman
- Yao Qizhi, M.D., Ph.D., Emory University, Atlanta, Ga.
- Shibo Jiang, M.D., Ph.D., New York Blood Center, New York City
- Louis D. Falo, M.D., Ph.D., University of Pittsburgh, Pa.
- Glenn Y. Ishioka, Ph.D., Cytel Corporation, San Diego, Calif.
- Ann B. Hill, Ph.D., Oregon Health Sciences University, Portland
- Samuel J. Landry, Ph.D., Tulane University, New Orleans, La.
- Cara C. Wilson, M.D., University of Pittsburgh, Pa.
- Don P. Wolf, Ph.D., Oregon Regional Primate Research Center,
- Carl T. Wild, Ph.D., Biotech Research Laboratories, Rockville, Md.
- Kunal Saha, M.D., Ph.D., St. Luke's Roosevelt Institute for Health
Sciences, New York City
- Miroslav Malkovsky, M.D., University of Wisconsin, Madison
- Kam W. Leong, Ph.D., Johns Hopkins University, Baltimore, Md.
- Richard Wyatt, Ph.D., Dana-Farber Cancer Institute, Boston, Mass.
- John P. Moore, Ph.D., Aaron Diamond AIDS Research Center, New
- Rafi Ahmed, Ph.D., Emory University, Atlanta, Ga.
- Yair Argon, Ph.D., University of Chicago, Ill.
Because of the importance and urgency that NIAID and the AVRC
place on AIDS vaccine development, NIAID piloted a new streamlined
grant award process with this program announcement. NIAID
published the call for applications in March 1997 and selected
recipients within six months. Based on the encouraging response from
the scientific community, a second program announcement is planned.
NIAID, a component of the National Institutes of Health (NIH),
conducts and supports research to prevent, diagnose and treat illnesses
such as AIDS and other sexually transmitted diseases, tuberculosis and
malaria, as well as asthma and allergies. NIH is an agency of the U.S.
Department of Health and Human Services.
Press releases, fact sheets and other NIAID-related materials are
available on the Internet via the NIAID home page at